Compare Ascendis Pharma A/S (ASND) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Carparts.Com Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Carparts.Com Inc trades at $5.87 (market cap $47.94M). The key difference: Ascendis Pharma A/S is far larger — about 370× Carparts.Com Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| ASND | PRTS | |
|---|---|---|
Market Cap | $17.74B | $47.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $11.40 |
52-Week Low | $163.32 | $3.88 |
Enterprise Value | $18.11B | $62.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PRTS trades at $5.87, down 1.92% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $50.44 million in 2025, though recent quarters have beaten EPS estimates. A recent reverse stock split and new credit facility aim to stabilize operations amid declining revenue trends from $676 million in 2023 to $548 million in 2025.
The outlook remains challenging with persistent losses and negative cash flow, but analyst consensus is positive with 60% buy ratings. Key risks include sustained unprofitability and competitive pressures, while potential upside hinges on cost control and execution of strategic initiatives to return to growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
